Procept BioRobotics Corp (PRCT) PT Raised to $75 at TD Cowen

TD Cowen analyst Joshua Jennings raised the price target on Procept BioRobotics Corp (NASDAQ: PRCT) to $75.00 (from $65.00) while maintaining a Buy rating.

The analyst commented, "PRCT unveiled its vision to become a leading global urology company during its investor event at AUA. The clinical value proposition of Aquablation therapy in BPH was showcased along with the potential for the therapy to fill an unmet clinical need in low and intermediate risk prostate cancer. PRCT remains on of the premier growth stories in our smid cap coverage."

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Power Solutions International, Inc. (NASDAQ: PSIX); and PROCEPT BioRobotics Corporation (
• Adyen NV (ADYEN:NA) (ADYYF) PT Raised to EUR1,278 at TD Cowen
• Freedom Broker Downgrades Holley (HLLY) to Hold